Frankfurt - Delayed Quote EUR

Kura Oncology, Inc. (KUR.F)

5.85
+0.03
+(0.45%)
At close: June 11 at 8:07:52 AM GMT+2

Research Analysis

Revenue vs. Earnings

Revenue 14.11M
Earnings -57.43M

Q2'24

Q3'24

Q4'24

Q1'25

-40M
-20M
0
20M
40M
 

Analyst Price Targets

Earnings Estimate

Currency in USD Current Qtr. (Jun 2025)Next Qtr. (Sep 2025)Current Year (2025)Next Year (2026)
No. of Analysts --------
Avg. Estimate 0000
Low Estimate 0000
High Estimate 0000
Year Ago EPS --------

Revenue Estimate

Currency in USD Current Qtr. (Jun 2025)Next Qtr. (Sep 2025)Current Year (2025)Next Year (2026)
No. of Analysts 13131314
Avg. Estimate 64.95M18.46M160.33M204M
Low Estimate ----19.31M20.05M
High Estimate 375M102.7M438.6M451.2M
Year Ago Sales ----53.88M160.33M
Sales Growth (year/est) 0.00%0.00%197.55%27.24%

EPS Trend

Currency in USD Current Qtr. (Jun 2025)Next Qtr. (Sep 2025)Current Year (2025)Next Year (2026)
Current Estimate 0000
7 Days Ago 0000
30 Days Ago 0000
60 Days Ago 0000
90 Days Ago 0000

EPS Revisions

Currency in USD Current Qtr. (Jun 2025)Next Qtr. (Sep 2025)Current Year (2025)Next Year (2026)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
KUR.F --------
S&P 500 13.13%2.46%7.54%14.07%

Upgrades & Downgrades

Reiterates JMP Securities: Market Outperform to Market Outperform 6/4/2025
Maintains Mizuho: Outperform to Outperform 5/19/2025
Maintains Barclays: Overweight to Overweight 5/2/2025
Reiterates JMP Securities: Market Outperform to Market Outperform 4/29/2025
Reiterates HC Wainwright & Co.: Buy to Buy 4/28/2025
Maintains UBS: Buy to Buy 3/6/2025

Related Tickers